Diabetes and Cardiovascular Disease: Epidemiology, Biological Mechanisms, Treatment Recommendations and Future Research

Overview

Journal World J Diabetes

Publisher Baishideng Publishing Group

Specialty Endocrinology

Date 2015 Oct 16

PMID 26468341

Citations 428

Authors

Benjamin M Leon

Thomas M Maddox

Affiliations

Soon will be listed here.

Abstract

The incidence of diabetes mellitus (DM) continues to rise and has quickly become one of the most prevalent and costly chronic diseases worldwide. A close link exists between DM and cardiovascular disease (CVD), which is the most prevalent cause of morbidity and mortality in diabetic patients. Cardiovascular (CV) risk factors such as obesity, hypertension and dyslipidemia are common in patients with DM, placing them at increased risk for cardiac events. In addition, many studies have found biological mechanisms associated with DM that independently increase the risk of CVD in diabetic patients. Therefore, targeting CV risk factors in patients with DM is critical to minimize the long-term CV complications of the disease. This paper summarizes the relationship between diabetes and CVD, examines possible mechanisms of disease progression, discusses current treatment recommendations, and outlines future research directions.

Citing Articles

Tissue factor pathway inhibitor levels and atherothrombotic events in patients with chronic kidney disease or diabetes.

Brook R, Suleiman M, Rigano J, Lui B, Nandurkar H, Ho P J Thromb Thrombolysis. 2025; .

PMID: 40064839 DOI: 10.1007/s11239-025-03077-3.

Chronic complications of type 2 diabetes and associated factors: a cross-sectional study at the Moulay Hassan Hospital in Kenitra, Morocco.

El Aameri M, Jaghror I, Meskini N, Benchehida H, Eladha I, Chakit M Pan Afr Med J. 2025; 49:84.

PMID: 40027088 PMC: 11871885. DOI: 10.11604/pamj.2024.49.84.42930.

PROGNOSTIC VALUES OF LIPID PANEL DATA FOR MACROVASCULAR COMPLICATION DEVELOPMENT IN TYPE 2 DIABETIC PATIENTS WITH COMORBID THYROID DYSFUNCTION.

Marushchak M, Krynytska I, Gashynska O, Yakymchuk O Acta Clin Croat. 2025; 63(1):89-100.

PMID: 39959321 PMC: 11827394. DOI: 10.20471/acc.2024.63.01.11.

Relationship Between Systemic Inflammatory Response Exponents, Levels of ADAM10, ADAM17 Proteins and Selected Clinical Parameters in Patients with Colorectal Cancer: Original Research Study.

Sikora-Skrabaka M, Walkiewicz K, Waniczek D, Strzelczyk J, Nowakowska-Zajdel E Int J Mol Sci. 2025; 26(3).

PMID: 39940871 PMC: 11817235. DOI: 10.3390/ijms26031104.

The Influence of Lifestyle Modifications on Cardiovascular Outcomes in Older Adults: Findings from a Cross-Sectional Study.

Almutairi M, Almutairi A, Alodhialah A Life (Basel). 2025; 15(1).

PMID: 39860027 PMC: 11767055. DOI: 10.3390/life15010087.

References

Kannel W . Lipids, diabetes, and coronary heart disease: insights from the Framingham Study. Am Heart J. 1985; 110(5):1100-7. DOI: 10.1016/0002-8703(85)90224-8. View

Matheus A, Tannus L, Cobas R, Palma C, Negrato C, Gomes M . Impact of diabetes on cardiovascular disease: an update. Int J Hypertens. 2013; 2013:653789. PMC: 3603160. DOI: 10.1155/2013/653789. View

Kim M, Oh J, Sakata S, Liang I, Park W, Hajjar R . Role of resistin in cardiac contractility and hypertrophy. J Mol Cell Cardiol. 2008; 45(2):270-80. PMC: 2613017. DOI: 10.1016/j.yjmcc.2008.05.006. View

Sacks D, Arnold M, Bakris G, Bruns D, Horvath A, Kirkman M . Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Diabetes Care. 2011; 34(6):e61-99. PMC: 3114322. DOI: 10.2337/dc11-9998. View

Cushman W, Evans G, Byington R, Goff Jr D, Grimm Jr R, Cutler J . Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010; 362(17):1575-85. PMC: 4123215. DOI: 10.1056/NEJMoa1001286. View

Leri A, Liu Y, Wang X, Kajstura J, Malhotra A, Meggs L . Overexpression of insulin-like growth factor-1 attenuates the myocyte renin-angiotensin system in transgenic mice. Circ Res. 1999; 84(7):752-62. DOI: 10.1161/01.res.84.7.752. View

Ernande L, Rietzschel E, Bergerot C, De Buyzere M, Schnell F, Groisne L . Impaired myocardial radial function in asymptomatic patients with type 2 diabetes mellitus: a speckle-tracking imaging study. J Am Soc Echocardiogr. 2010; 23(12):1266-72. DOI: 10.1016/j.echo.2010.09.007. View

Boden W, Probstfield J, Anderson T, Chaitman B, Desvignes-Nickens P, Koprowicz K . Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011; 365(24):2255-67. DOI: 10.1056/NEJMoa1107579. View

Wolf G, Ziyadeh F . The role of angiotensin II in diabetic nephropathy: emphasis on nonhemodynamic mechanisms. Am J Kidney Dis. 1997; 29(1):153-63. DOI: 10.1016/s0272-6386(97)90023-8. View

10.

. Economic costs of diabetes in the U.S. In 2007. Diabetes Care. 2008; 31(3):596-615. DOI: 10.2337/dc08-9017. View

11.

Hamilton S, Watts G . Endothelial dysfunction in diabetes: pathogenesis, significance, and treatment. Rev Diabet Stud. 2014; 10(2-3):133-56. PMC: 4063100. DOI: 10.1900/RDS.2013.10.133. View

12.

Solano M, Goldberg R . Management of dyslipidemia in diabetes. Cardiol Rev. 2006; 14(3):125-35. DOI: 10.1097/01.crd.0000188034.76283.5e. View

13.

Krakoff L, Gillespie R, Ferdinand K, Fergus I, Akinboboye O, Williams K . 2014 hypertension recommendations from the eighth joint national committee panel members raise concerns for elderly black and female populations. J Am Coll Cardiol. 2014; 64(4):394-402. PMC: 4242519. DOI: 10.1016/j.jacc.2014.06.014. View

14.

King P, Peacock I, Donnelly R . The UK prospective diabetes study (UKPDS): clinical and therapeutic implications for type 2 diabetes. Br J Clin Pharmacol. 1999; 48(5):643-8. PMC: 2014359. DOI: 10.1046/j.1365-2125.1999.00092.x. View

15.

ONeil P, Smith S, Weissman N, Fidler M, Sanchez M, Zhang J . Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring). 2012; 20(7):1426-36. DOI: 10.1038/oby.2012.66. View

16.

Colhoun H, Betteridge D, Durrington P, Hitman G, Neil H, Livingstone S . Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004; 364(9435):685-96. DOI: 10.1016/S0140-6736(04)16895-5. View

17.

Kajstura J, Fiordaliso F, Andreoli A, Li B, Chimenti S, Medow M . IGF-1 overexpression inhibits the development of diabetic cardiomyopathy and angiotensin II-mediated oxidative stress. Diabetes. 2001; 50(6):1414-24. DOI: 10.2337/diabetes.50.6.1414. View

18.

Wing R, Bolin P, Brancati F, Bray G, Clark J, Coday M . Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013; 369(2):145-54. PMC: 3791615. DOI: 10.1056/NEJMoa1212914. View

19.

Jensen M, Ryan D, Apovian C, Ard J, Comuzzie A, Donato K . 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation. 2013; 129(25 Suppl 2):S102-38. PMC: 5819889. DOI: 10.1161/01.cir.0000437739.71477.ee. View

20.

Aasum E, Hafstad A, Severson D, Larsen T . Age-dependent changes in metabolism, contractile function, and ischemic sensitivity in hearts from db/db mice. Diabetes. 2003; 52(2):434-41. DOI: 10.2337/diabetes.52.2.434. View